Clinical Trial

Buprenorphine for Individuals in Jail

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-08-31 -> 2029-01-01 2026-05-23
minor Completion moved earlier: 2029-12-31 -> 2029-04-30 2026-05-23
Trial Details
NCT Number NCT06306443
Lead Sponsor Friends Research Institute, Inc.
Conditions Opioid Use Disorder
Enrollment 240 participants
Start Date 2025-06-20
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-04